S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
The gold catalyst we’ve waited for (Ad)
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
The gold catalyst we’ve waited for (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
The gold catalyst we’ve waited for (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
The gold catalyst we’ve waited for (Ad)
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
The gold catalyst we’ve waited for (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
The gold catalyst we’ve waited for (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
The gold catalyst we’ve waited for (Ad)
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
The gold catalyst we’ve waited for (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
The gold catalyst we’ve waited for (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
The gold catalyst we’ve waited for (Ad)
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
The gold catalyst we’ve waited for (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
The gold catalyst we’ve waited for (Ad)
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
NASDAQ:FLGT

Fulgent Genetics - FLGT Stock Forecast, Price & News

$31.12
+0.97 (+3.22%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$29.93
$31.17
50-Day Range
$30.15
$36.27
52-Week Range
$28.53
$65.32
Volume
174,978 shs
Average Volume
315,063 shs
Market Capitalization
$918.66 million
P/E Ratio
6.82
Dividend Yield
N/A
Price Target
$41.67

Fulgent Genetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
33.9% Upside
$41.67 Price Target
Short Interest
Healthy
4.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.90mentions of Fulgent Genetics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.25) to ($1.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

97th out of 1,005 stocks

Medical Laboratories Industry

4th out of 26 stocks


FLGT stock logo

About Fulgent Genetics (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in Temple City, CA.

Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Fulgent Genetics, Inc. (FLGT)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Q4 2022 Fulgent Genetics Inc Earnings Call
This Medical Play Is Up to the Test
My Top 7 Strong Conviction Buys for 2023
At EV/Sales Below 1x, Fulgent Is Undervalued
Where Fulgent Genetics Stands With Analysts
See More Headlines
Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Company Calendar

Last Earnings
2/28/2023
Today
3/25/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FLGT
Employees
1,012
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$41.67
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+33.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$143.40 million
Pretax Margin
29.73%

Debt

Sales & Book Value

Annual Sales
$618.97 million
Cash Flow
$6.75 per share
Book Value
$43.14 per share

Miscellaneous

Free Float
20,811,000
Market Cap
$918.66 million
Optionable
Not Optionable
Beta
1.61

Social Links


Key Executives

  • Ming HsiehMing Hsieh
    Chairman & Chief Executive Officer
  • James Xie
    President & Chief Operating Officer
  • Paul H. KimPaul H. Kim
    Chief Financial Officer
  • Harry Gao
    Chief Scientific Officer & Laboratory Director
  • Lawrence M. Weiss
    Chief Medical Officer













FLGT Stock - Frequently Asked Questions

Should I buy or sell Fulgent Genetics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FLGT shares.
View FLGT analyst ratings
or view top-rated stocks.

What is Fulgent Genetics' stock price forecast for 2023?

3 brokers have issued twelve-month price targets for Fulgent Genetics' stock. Their FLGT share price forecasts range from $35.00 to $45.00. On average, they predict the company's stock price to reach $41.67 in the next twelve months. This suggests a possible upside of 33.9% from the stock's current price.
View analysts price targets for FLGT
or view top-rated stocks among Wall Street analysts.

How have FLGT shares performed in 2023?

Fulgent Genetics' stock was trading at $29.78 at the beginning of the year. Since then, FLGT shares have increased by 4.5% and is now trading at $31.12.
View the best growth stocks for 2023 here
.

When is Fulgent Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our FLGT earnings forecast
.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.07. The firm had revenue of $67.70 million for the quarter, compared to analysts' expectations of $59.44 million. Fulgent Genetics had a trailing twelve-month return on equity of 11.93% and a net margin of 23.17%.

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its first quarter 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $56.00 million-$56.00 million, compared to the consensus revenue estimate of $60.92 million.

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.71%), Pacer Advisors Inc. (1.98%), Geode Capital Management LLC (1.34%), JPMorgan Chase & Co. (1.15%), Morgan Stanley (0.90%) and American Century Companies Inc. (0.81%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends
.

How do I buy shares of Fulgent Genetics?

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $31.12.

How much money does Fulgent Genetics make?

Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $918.66 million and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or $4.56 on an earnings per share basis.

How many employees does Fulgent Genetics have?

The company employs 1,012 workers across the globe.

Does Fulgent Genetics have any subsidiaries?
The following companies are subsidiares of Fulgent Genetics: CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, Fulgent Therapeutics LLC, and Inform Diagnostics.
Read More
How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667.

This page (NASDAQ:FLGT) was last updated on 3/25/2023 by MarketBeat.com Staff